Resumen de Investigación

Early use of effective therapies may improve diabetes outcomes

Moderate confidence
Low bias
Última actualización 13 de junio de 2026

Conclusión Clave:

This study evaluated the cost-effectiveness of various glucose-lowering agents in type 2 diabetes patients, finding significant reductions in HbA1c levels.

Estudio de un Vistazo

Participantes

Intervención

Metformin, Empagliflozin 10 mg, Tirzepatide 10 mg, Liraglutide 1.8 mg, Semaglutide 1.0 mg, Dulaglutide 3.0 mg

Resultados

HbA1c, Systolic Blood Pressure (SBP), LDL Cholesterol, HDL Cholesterol, Body Mass Index (BMI), Estimated Glomerular Filtration Rate (eGFR), Non-severe Hypoglycemia Rate, Severe Hypoglycemia Rate

Financiamiento

No Patrocinado por la Industria

Guarda este estudio y agrega notas a tu biblioteca de investigación.

Efectos Principales

HbA1c decreased by 2.37% with the most effective intervention.

HbA1c decreased by 1.86% with another intervention.

HbA1c decreased by 1.12% with a different treatment.

Resumen de Evidencia

InterventionOutcomeMeasured ChangeStudy Effect
Medications
Metformin
(Medications)
Weight & Anthropometrics
BMI
(Weight & Anthropometrics)
Decrease
Strong
Medications
Metformin
(Medications)
Clinical Outcomes
Estimated glomerular filtration rate
(Clinical Outcomes)
No Change
Unclear
Medications
Metformin
(Medications)
Glycemic Control
HbA1c
(Glycemic Control)
Decrease
Strong
Medications
Metformin
(Medications)
Metabolic Health
HDL cholesterol
(Metabolic Health)
Increase
Strong
Medications
Metformin
(Medications)
Metabolic Health
LDL cholesterol
(Metabolic Health)
Decrease
Strong
Medications
Metformin
(Medications)
Safety
Severe hypoglycemia
(Safety)
Decrease
Strong
Medications
Metformin
(Medications)
Metabolic Health
Systolic blood pressure
(Metabolic Health)
Decrease
Strong

Unlock Full Evidence Analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

evidence suggest

La Evidencia Sugiere

  • HbA1c decreased by 2.37% with the most effective intervention.
  • HbA1c decreased by 1.86% with another intervention.
  • HbA1c decreased by 1.12% with a different treatment.
keep in mind

Tener en Cuenta

  • Effectiveness of some interventions was unclear.
  • Limited generalizability due to the modeling approach.
  • Potential unmeasured confounders affecting outcomes.
between the lines

Entre Líneas

  • Effectiveness of some interventions was unclear.
  • Limited generalizability due to the modeling approach.
  • Potential unmeasured confounders affecting outcomes.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Referencia de la Revista

Meredith H, Alice M, William JV. Modeling Analysis of Treatment Pathways for Type 2 Diabetes in the US. Diabetes Therapy. 2026. doi:10.1007/s13300-026-01846-8

View DOIView on PubMedView on PMC

Connected Evidence

Discover how this study fits into the broader diabetes evidence landscape.

This study contributes to evidence on GLP-1 Receptor Agonists and Glycemic Control, GLP-1 Receptor Agonists and Body Weight.

Relaciones de evidencia relacionadas

Explore in Evidence Archive

This study contributes to the evidence on the following intervention–outcome relationships.

Preguntas que esta evidencia ayuda a responder

Key clinical and research questions this study contributes to.

Does liraglutide improve HbA1c?

Based on connected evidence for Liraglutide and HbA1c.

Does semaglutide affect BMI in people with diabetes?

Exploring evidence on Semaglutide and BMI outcomes.

What does the evidence say about metformin and HDL cholesterol?

Review of studies examining Metformin and HDL cholesterol.

Cómo se generan las conexiones

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.